http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2135221-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8a0e90292f2ba83d7878baca3838b8a2 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-252 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-252 |
| filingDate | 1972-05-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1972-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | FR-2135221-A1 |
| titleOfInvention | Doxorubicin 14-esters prepn - by treating 14-bromodaunomycin with a salt of the corresp acid |
| abstract | Doxorubicin 14-esters of a mono- or dicarboxylic aliphatic, aromatic, cycloaliphatic, araliphatic or heterocyclic acid (1-20C) opt. substd. by halogen, OH, alkyl, alkoxy, NH2, NO2; mono- or dialkyl substd. alkyl- or arylcarbonic acids; carbamic acids, alkylcarbamic acids, and sulphonic acids; also their acid-addn. salts. They are prepd. by treating 14-bromodaunomycin or a salt with a salt of the required acid with an alkali metal, an alkaline earth metal or a quaternary ammonium gp., opt. alkylated. The reaction medium is pref. an inert polar solvent, e.g. acetone. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/FR-2361417-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6702705-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0424899-A3 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0424899-A2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6258360-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0746336-A4 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0746336-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4299822-A |
| priorityDate | 1971-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 24.